<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310479</url>
  </required_header>
  <id_info>
    <org_study_id>GU-6-0062 / 22281</org_study_id>
    <nct_id>NCT00310479</nct_id>
  </id_info>
  <brief_title>Clinico-pathologic Correlative Study of 3T Magnetic Resonance Spectroscopy in the Localization of Prostate Cancer</brief_title>
  <official_title>Clinico-pathologic Correlative Study of 3T Magnetic Resonance Spectroscopy in the Localization of Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHS Cancer Control Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cross Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We seek to develop an advanced imaging approach to identifying and localizing prostate&#xD;
      cancer. We believe that high field MRI (magnetic resonance imaging) has the potential to do&#xD;
      this and we will endeavor to prove this by having patients with prostate cancer&#xD;
      pre-operatively undergo a technique called magnetic resonance spectroscopy. After surgery,&#xD;
      the microscopic locations of cancer will be compared with the pre-operative images to assess&#xD;
      how well the imaging technique succeeds.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The proposed research is enormously relevant to the clinical understanding of early prostate&#xD;
      cancer. We propose to test to see whether characteristic patterns of invivo 3T MRSI&#xD;
      associated metabolites can be identified in correlation with clinically active tumor reserved&#xD;
      on histopathologic analysis of resected specimens. We also plan to demonstrate that 3T MR&#xD;
      spectra of prostate cancer will allow for more detailed metabolic assessment with higher&#xD;
      sensitivity, specificity and accuracy and publish results established from MR spectra using&#xD;
      1.5T MR units. Functional imaging (eg. molecular imaging such as this) is felt to be the&#xD;
      clinical wave of the future for cancer imaging, and if successful, will assume a very major&#xD;
      role in the detection, assessment, treatment planning and delivery of drugs, radiation, heat&#xD;
      and novel therapeutics in the fight against prostate cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>characteristic metabolic pattern of prostate cancer at 3Tesla</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>specificity, accuracy, NPV</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PPV of MRS in the detection of prostate cancer</measure>
  </secondary_outcome>
  <enrollment type="Actual">16</enrollment>
  <condition>Prostate Cancer</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Magnetic Resonance Spectroscopy (3Tesla)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically verified prostate cancer&#xD;
&#xD;
          -  Patient has opted for surgery&#xD;
&#xD;
          -  Low risk prostate cancer PSA &lt;1 0, Gleason &lt; 7, Stage &lt; T2b&#xD;
&#xD;
          -  No contraindication to MR scanning&#xD;
&#xD;
          -  No prior history of malignancy&#xD;
&#xD;
          -  Fit for surgery&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Nonbiopsied lesion&#xD;
&#xD;
          -  Intermediate or high risk prostate cancer&#xD;
&#xD;
          -  Unfit for surgery&#xD;
&#xD;
          -  Contraindication to MR scanning (i.e. pacemaker, aneurysm clips, claustrophobia)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew Parliament, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AHS Cancer Control Alberta</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>April 3, 2006</study_first_submitted>
  <study_first_submitted_qc>April 3, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2006</study_first_posted>
  <last_update_submitted>February 24, 2016</last_update_submitted>
  <last_update_submitted_qc>February 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>prostate cancer imaging</keyword>
  <keyword>3T MRS</keyword>
  <keyword>functional imaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

